Literature DB >> 33347425

The impact of physical frailty on the response to inactivated influenza vaccine in older adults.

Krissy K Moehling1,2, Bo Zhai3, William E Schwarzmann4, Uma R Chandran4, Marianna Ortiz3, Mary Patricia Nowalk1, David Nace5, Chyongchiou J Lin1,6, Michael Susick1, Min Z Levine7, John F Alcorn3, Richard K Zimmerman1.   

Abstract

Physical frailty's impact on hemagglutination inhibition antibody titers (HAI) and peripheral blood mononuclear cell (PBMC) transcriptional responses after influenza vaccination is unclear. Physical frailty was assessed using the 5-item Fried frailty phenotype in 168 community- and assisted-living adults ≥55 years of age during an observational study. Blood was drawn before, 3, 7, and 28 days post-vaccination with the 2017-2018 inactivated influenza vaccine. HAI response to the A/H1N1 strain was measured at Days 0 and 28 using seropositivity, seroconversion, log2 HAI titers, and fold-rise in log2 HAI titers. RNA sequencing of PBMCs from Days 0, 3 and 7 was measured in 28 participants and compared using pathway analyses. Frailty was not significantly associated with any HAI outcome in multivariable models. Compared with non-frail participants, frail participants expressed decreased cell proliferation, metabolism, antibody production, and interferon signaling genes. Conversely, frail participants showed elevated gene expression in IL-8 signaling, T-cell exhaustion, and oxidative stress pathways compared with non-frail participants. These results suggest that reduced effectiveness of influenza vaccine among older, frail individuals may be attributed to immunosenescence-related changes in PBMCs that are not reflected in antibody levels.

Entities:  

Keywords:  antibody titers; frailty; immune response; influenza; peripheral cell mediated immunity

Mesh:

Substances:

Year:  2020        PMID: 33347425      PMCID: PMC7803506          DOI: 10.18632/aging.202207

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  61 in total

Review 1.  Frailty in older adults: insights and interventions.

Authors:  Sara Espinoza; Jeremy D Walston
Journal:  Cleve Clin J Med       Date:  2005-12       Impact factor: 2.321

2.  Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection.

Authors:  Beth McNally; Fang Ye; Meredith Willette; Emilio Flaño
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

3.  Update on vaccination guidelines for older adults.

Authors:  Mark Alexander Pilkinton; H Keipp Talbot
Journal:  J Am Geriatr Soc       Date:  2015-03-06       Impact factor: 5.562

Review 4.  Oxidative stress, genomic features and DNA repair in frail elderly: A systematic review.

Authors:  María Sánchez-Flores; Diego Marcos-Pérez; Solange Costa; João Paulo Teixeira; Stefano Bonassi; Eduardo Pásaro; Blanca Laffon; Vanessa Valdiglesias
Journal:  Ageing Res Rev       Date:  2017-05-06       Impact factor: 10.895

5.  Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.

Authors:  Raquel G Cao; Nicolas M Suarez; Gerlinde Obermoser; Santiago M C Lopez; Emilio Flano; Sara E Mertz; Randy A Albrecht; Adolfo García-Sastre; Asuncion Mejias; Hui Xu; Huanying Qin; Derek Blankenship; Karolina Palucka; Virginia Pascual; Octavio Ramilo
Journal:  J Infect Dis       Date:  2014-02-04       Impact factor: 5.226

6.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

Review 7.  Ribosomopathies: There's strength in numbers.

Authors:  Eric W Mills; Rachel Green
Journal:  Science       Date:  2017-11-03       Impact factor: 47.728

Review 8.  Prevalence of frailty in community-dwelling older persons: a systematic review.

Authors:  Rose M Collard; Han Boter; Robert A Schoevers; Richard C Oude Voshaar
Journal:  J Am Geriatr Soc       Date:  2012-08-06       Impact factor: 5.562

9.  Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.

Authors:  Heinz Läubli; Catharina Balmelli; Lukas Kaufmann; Michal Stanczak; Mohammedyaseen Syedbasha; Dominik Vogt; Astrid Hertig; Beat Müller; Oliver Gautschi; Frank Stenner; Alfred Zippelius; Adrian Egli; Sacha I Rothschild
Journal:  J Immunother Cancer       Date:  2018-05-22       Impact factor: 13.751

Review 10.  Host susceptibility to severe influenza A virus infection.

Authors:  Sara Clohisey; John Kenneth Baillie
Journal:  Crit Care       Date:  2019-09-05       Impact factor: 9.097

View more
  4 in total

Review 1.  Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults.

Authors:  Janna R Shapiro; Rosemary Morgan; Sean X Leng; Sabra L Klein
Journal:  Front Aging       Date:  2022-02-11

2.  Sex-specific effects of aging on humoral immune responses to repeated influenza vaccination in older adults.

Authors:  Janna R Shapiro; Huifen Li; Rosemary Morgan; Yiyin Chen; Helen Kuo; Xiaoxuan Ning; Patrick Shea; Cunjin Wu; Katherine Merport; Rayna Saldanha; Suifeng Liu; Engle Abrams; Yan Chen; Denise C Kelly; Eileen Sheridan-Malone; Lan Wang; Scott L Zeger; Sabra L Klein; Sean X Leng
Journal:  NPJ Vaccines       Date:  2021-12-09       Impact factor: 7.344

3.  Influenza infection is not associated with phenotypical frailty in older patients, a prospective cohort study.

Authors:  Paul Takahashi; Chung-Il Wi; Euijung Ryu; Katherine King; Joel Hickman; Robert Pignolo; Young Juhn
Journal:  Health Sci Rep       Date:  2022-08-14

4.  Sex-specific transcriptome differences in a middle-aged frailty cohort.

Authors:  Natasha L Pacheco; Nicole Noren Hooten; Yongqing Zhang; Calais S Prince; Nicolle A Mode; Ngozi Ezike; Kevin G Becker; Alan B Zonderman; Michele K Evans
Journal:  BMC Geriatr       Date:  2022-08-09       Impact factor: 4.070

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.